2 citations
,
April 2025 in “Journal of Investigative Dermatology” T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.
2 citations
,
August 2024 in “JID Innovations” This study suggests that keratinocytes derived from hair follicles of patients with atopic dermatitis provide a useful model for investigating AD-related inflammation, as they showed greater expression changes of AD markers when stimulated with type 2 cytokines compared to those from healthy donors.
2 citations
,
August 2023 in “Molecules” This study found that a quinazoline derivative, SH-340, increased skin barrier-associated factors and inhibited TSLP expression and STAT6 phosphorylation in human primary keratinocytes, suggesting potential benefits for alleviating inflammation and improving skin barrier function in atopic dermatitis.
2 citations
,
September 2022 in “Frontiers in Immunology” This article reviews the emerging non-inflammatory roles of regulatory T cells in the skin and reports no new clinical findings, suggesting broad biological influence beyond traditional immune functions.
2 citations
,
June 2018 in “The Medical Journal of Cairo University/The Medical Journal of Cairo University” This study found that while Platelet Rich Plasma injections led to some clinical and immunological improvements in psoriatic plaques, it could not be recommended as a standalone treatment for localized plaque psoriasis.
2 citations
,
February 2018 in “InTech eBooks” This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.
1 citations
,
January 2026 in “Dermatology Reports” This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.
1 citations
,
May 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” This systematic review reported an association between specific interleukin gene polymorphisms (IL-17A, IL-18, IL17RA, and IL16) and alopecia areata, suggesting further genetic studies are needed to confirm the interleukins' role in the disorder's progression.
1 citations
,
January 2025 in “Frontiers in Immunology” In this study, researchers found that cytokine dysregulation linked to genetic background is present in both patients and healthy but genetically related individuals in two autoimmune skin diseases, Pemphigus vulgaris and Alopecia areata, suggesting that protective immune mechanisms may prevent disease manifestation in predisposed individuals.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
1 citations
,
March 2024 in “International journal of molecular sciences” This review discusses how ionizing radiation causes skin damage by inducing cellular senescence in keratinocytes, which secrete inflammatory mediators, recruiting immune cells and exacerbating inflammation, impacting the skin barrier function and healing.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.
1 citations
,
April 2023 in “World Journal of Urology” In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.
1 citations
,
January 2023 in “International Journal of Molecular Sciences” This review explores the role of Tregs in autoimmune skin diseases, transplantation, and skin cancer, and discusses Tregs-based therapies' potential for treating autoimmunity without reporting new experimental results.
1 citations
,
October 2022 in “JCI insight” In this study, conditional deletion of BRD4 in OX40-expressing cells of mice led to alopecia, dermatitis, and loss of hair follicle stem cell function, revealing BRD4's role in skin inflammation and stem cell regulation.
1 citations
,
May 2021 in “Cell Host & Microbe” This study reports that skin bacteria can accelerate hair follicle regeneration and improve wound healing through IL-1β signaling, by activating keratinocytes in a pathway involving IL1R/Myd88.
May 2026 in “Frontiers in Immunology” This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.
May 2026 in “SKIN The Journal of Cutaneous Medicine” This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.
This review highlights that iron deficiency is a significant yet often overlooked contributor to the development of immune-mediated inflammatory skin diseases, suggesting that iron dysregulation may drive inflammation and metabolic imbalances in conditions like psoriasis and atopic dermatitis.
March 2026 in “Biomedicines” This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.
October 2025 in “Australasian Journal of Dermatology” In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.
September 2025 in “Frontiers in Immunology” This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.
September 2025 in “Diseases” This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.
In this study assessing post-menopausal Asian women, distinct shifts in Malassezia species prevalence on the skin were linked to increased inflammation and impaired skin barrier function, potentially driving disorders like psoriasis and seborrheic dermatitis.
May 2025 in “International Journal of Molecular Sciences” This study found that exosomes and secretome derived from rat hair follicle stem cells show promising potential for wound healing and tissue repair, demonstrating significant wound closure and suggesting their broader applicability in regenerative medicine.
This study observed that, among alopecia areata patients in Fujian, China, lower IgG4 levels and higher IFN-γ levels were statistically significant, suggesting their potential role as biomarkers for the condition and highlighting avenues for future therapeutic developments.
January 2025 in “International Journal of Molecular Sciences” This narrative review explored the complex interconnections between psoriasis and other dermatological conditions like vitiligo, alopecia areata, and atopic dermatitis, highlighting shared immune dysfunctions that complicate diagnosis and treatment, with implications for research and holistic patient care.
November 2024 in “Journal of Investigative Dermatology” Secukinumab reduces immune activity in hidradenitis suppurativa skin.
November 2024 in “International Journal of Molecular Sciences” In this review, the authors discuss how hair may protect against scalp skin cancer by enabling IL-17-biased immunosurveillance, while hair loss could permit tumor development by reducing this immune protection.